Neurology

Assure Holdings Closes Sale of Certain Assets to MPOWERHealth

DENVER, March 28, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative…

4 months ago

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

WARREN, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech…

4 months ago

Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024

LRK-A drives monotherapy anti-tumor activity, including complete tumor regressions, in CRC patient samples and an in vivo modelIND-enabling studies are…

4 months ago

PhotoPharmics Launches Largest Phototherapy Trial for Parkinson’s Disease

Pivotal Trial for Improving Overall Function and Quality of LifeSALT LAKE CITY--(BUSINESS WIRE)--#medicaldevices--PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative…

4 months ago

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m.…

4 months ago

Essential Pharma and AcedrA Biopharmaceuticals sign Distribution Agreement to commercialize essential medicines in the Middle East and North Africa region

ZUG, Switzerland and EGHAM, United Kingdom and RIYADH, Saudi Arabia, March 26, 2024 (GLOBE NEWSWIRE) -- Essential Pharma, an international…

4 months ago

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company…

4 months ago

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney…

4 months ago

AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC’s 23M AiBtl Share Ownership as Hundred Million Dollars

FREMONT, CA, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire  – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical…

4 months ago